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Activation of the Cyclin B/Cdc2 kinase complex triggers entry into mitosis in all eukaryotic cells. Cyclin B1
localization changes dramatically during the cell cycle, precipitously transiting from the cytoplasm to the
nucleus at the beginning of mitosis. Presumably, this relocalization promotes the phosphorylation of nuclear
targets critical for chromatin condensation and nuclear envelope breakdown. We show here that the
previously characterized cytoplasmic retention sequence of Cyclin B1, responsible for its interphase
cytoplasmic localization, is actually an autonomous nuclear export sequence, capable of directing nuclear
export of a heterologous protein, and able to bind specifically to the recently identified export mediator,
CRM1. We propose that the observed cytoplasmic localization of Cyclin B1 during interphase reflects the
equilibrium between ongoing nuclear import and rapid CRM1-mediated export. In support of this hypothesis,
we found that treatment of cells with leptomycin B, which disrupted Cyclin B1–CRM1 interactions, led to a
marked nuclear accumulation of Cyclin B1. In mitosis, Cyclin B1 undergoes phosphorylation at several sites,
a subset of which have been proposed to play a role in Cyclin B1 accumulation in the nucleus. Both CRM1
binding and the ability to direct nuclear export were affected by mutation of these phosphorylation sites; thus,
we propose that Cyclin B1 phosphorylation at the G2/M transition prevents its interaction with CRM1,
thereby reducing nuclear export and facilitating nuclear accumulation.
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Entry into mitosis in eukaryotic cells is controlled by
activation of the Ser/Thr kinase Cdc2 bound to one of
several B-type cyclins. Although Cyclin B proteins are
synthesized and can interact with Cdc2 during inter-
phase, Cdc2/Cyclin B complexes are held in an inactive
state until the G2/M transition. This inactivation of
Cdc2/Cyclin B during interphase is achieved through in-
hibitory phosphorylation of the Cdc2 subunit on Thr-14
and Tyr-15 by the Wee1 and Myt1 kinases, thus prevent-
ing premature initiation of mitosis (Norbury et al. 1991;
Krek et al. 1992; Solomon et al. 1992; Atherton-Fessler et
al. 1994; Kornbluth et al. 1994; Watanabe et al. 1994;
McGowan et al. 1995; Mueller et al. 1995a,b). Dephos-
phorylation of Cdc2 by the dual specificity Cdc25 phos-
phatase then leads to activation of the Cdc2/Cyclin B
kinase(s) and entry into mitosis (Dunphy and Kumagai
1991; Gautier et al. 1991; Strausfeld et al. 1991; Millar
and Russell 1992).
Another aspect of mitotic regulation was revealed by
the discovery that both the Cdc2/Cyclin complexes and
their regulatory enzymes were concentrated in specific
subcellular compartments. In HeLa cells, Cdc2/Cyclin
B2 complexes are constitutively cytoplasmic, and prima-
rily associated with the Golgi during interphase (Jack-
man et al. 1995). In contrast, Cdc2/Cyclin B1 complexes
associate with microtubules during interphase, but tran-
sit precipitously into the nucleus at the G2/M transition,
presumably to allow phosphorylation of nuclear sub-
strates critical for mitosis. The Wee1 kinase, which
negatively regulates Cdc2/Cyclin B through phosphory-
lation at Tyr-15 of Cdc2, is predominantly nuclear
(Heald et al. 1993; Wu et al. 1996), whereas the Myt1
kinase, which can phosphorylate both Tyr-15 and Thr-
14, is associated with the cytoplasmic face of the endo-
plasmic reticulum and Golgi (Liu et al. 1997). The local-
ization of the Cdc25 phosphatase, which dephosphory-
lates these sites, has been somewhat controversial
(Millar et al. 1991; Girard et al. 1992; Izumi et al. 1992;
Seki et al. 1992; Heald et al. 1993), but it appears that
different Cdc25 isoforms may be restricted to the
nucleus or cytoplasm, perhaps in a cell-type-specific
manner.
The finding that Cdc2/Cyclin B complexes and their
3Corresponding author.
E-MAIL kornb001@mc.duke.edu; FAX (919) 613-8642.
GENES & DEVELOPMENT 12:2131–2143 © 1998 by Cold Spring Harbor Laboratory Press ISSN 0890-9369/98 $5.00; www.genesdev.org 2131
regulators appear to be restricted in subcellular localiza-
tion has important implications for the regulation of en-
try into mitosis, because particular regulators of Cdc2
may only have access to a subset of Cdc2/cyclin com-
plexes. Furthermore, distinct Cdc2/cyclin complexes
may be responsible for different aspects of mitosis be-
cause their accessibility to key substrates will depend on
their localization. Coordination between the nuclear
events of mitosis (e.g., nuclear envelope breakdown,
chromosome condensation) and the cytoplasmic events
of mitosis (e.g., Golgi disassembly, spindle formation)
requires appropriately timed activation of Cdc2/Cyclin
B kinases in both subcellular compartments. Thus, the
mechanisms underlying the subcellular distribution of
these key regulators are of great interest for understand-
ing the regulated and concerted nature of the G2/M tran-
sition.
Recent work by a number of groups has revealed that
nuclear trafficking of proteins is mediated by a family of
saturable receptors that cooperate with soluble factors
and nuclear pore proteins to move transport cargo in and
out of the nucleus (for review, see Gorlich and Mattaj
1996; Corbett et al. 1997; Doye et al. 1997; Ullman et al.
1997). Recently, several such receptors have been discov-
ered, including the importin a/b heterodimer, which
mediates binding to classical nuclear localization se-
quences (NLSs) (Gorlich et al. 1994, 1995; Radu et al.
1995), transportin, which binds to a nuclear shuttling
sequence (M9 confers bidirectional transport) (Pollard et
al. 1996), and CRM1, a receptor for leucine-rich nuclear
export sequences (NESs) (Fornerod et al. 1997; Fukuda et
al. 1997; Neville et al. 1997; Ossareh-Nazari et al. 1997;
Stade et al. 1997).
Analysis of chimeras between human Cyclin A (which
is constitutively nuclear) and human Cyclin B1 in HeLa
cells led to the discovery of a domain of Cyclin B1
(amino acids 109–151), which was necessary for the in-
terphase localization of Cyclin B1 and sufficient to target
Cyclin A to the cytoplasm (Pines et al. 1994). This do-
main was called the cytoplasmic retention sequence
(CRS), based on the hypothesis that it acts as an anchor-
ing site to tether Cyclin B1 to cytoplasmic components.
In this report we show that rather than promoting cyto-
plasmic retention, the Cyclin B1 CRS is actually an NES
that can autonomously direct export of a heterologous
protein and confers binding to the nuclear export recep-
tor, CRM1. Our results imply that the predominantly
cytoplasmic accumulation of Cyclin B1 in interphase re-
sults from continuous nuclear import and rapid re-export
rather than cytoplasmic immobilization.
In Xenopus, the CRS region of Cyclin B1, which is
61% identical to that of human Cyclin B1, contains four
conserved serine phosphorylation sites. Mutation of
these sites to alanine abolished the ability of the cyclin
to promote oocyte maturation (Li et al. 1995, 1997). Bio-
logical activity was restored to this mutant when a
nuclear localization sequence was fused to the amino
terminus of the protein, suggesting that CRS phosphory-
lation might be important for nuclear accumulation of
Cyclin B1 during oocyte maturation. We demonstrate
here that binding of the CRS to CRM1 is inhibited by
phosphorylation within the CRS, suggesting that cyclin
phosphorylation can reduce its rate of nuclear export,
promoting nuclear accumulation and entry into mitosis.
Results
Because Cyclin B1 phosphorylation site mutants have
been phenotypically characterized in Xenopus oocytes
and oocytes provide an experimentally tractable system
in which to study nuclear transport, we wished to exam-
ine the regulation of Cyclin B1 localization in this sys-
tem. Xenopus oocytes, which are physiologically ar-
rested in G2, were manually separated into nuclear and
cytosplasmic fractions. We found that Cyclin B1 was
predominantly cytoplasmic (Fig. 1A), with a small frac-
tion of the Cyclin B1 in the nucleus (germinal vesicle,
GV). In theory, this cytoplasmic accumulation of Cyclin
B1 could be the result of a lack of nuclear import (as
would occur if the CRS bound to a cytoplasmic anchor)
or to a steady state in which nuclear export of Cyclin B1
was more rapid than its import. To determine whether
Cyclin B1 could serve as a nuclear export substrate, full-
length Cyclin B1 was translated in vitro in reticulocyte
lysates in the presence of [35S]methionine and injected
into nuclei of stage VI oocytes. Immediately after injec-
tion or 4 hr after injection, the oocytes were dissected
manually into nuclear and cytoplasmic fractions. Suc-
Figure 1. Characterization of Cyclin B1 nuclear export in
Xenopus oocytes. (A) One, two, or five Xenopus stage VI oocytes
were manually dissected into cytoplasmic and nuclear fractions
and the distribution of endogenous Cyclin B1 was analyzed by
SDS-PAGE followed by Western blotting with anti-Cyclin B1
sera. (T,C,N) Proteins extracted from total oocytes, cytoplasmic
or nuclear fractions. Cdc25, which is cytoplasmic in oocytes,
was used as a control. (B) Cyclin B1 was translated in reticulo-
cyte lysates in the presence of [35S]methionine and injected into
Xenopus oocyte nuclei along with 14C-labeled BSA. At 0 and 4
hr after injection, the oocytes were dissected and successfully
injected oocytes were identified by the presence of pink coloring
from the reticulocyte lysate. These oocytes were separated into
cytoplasmic and nuclear fractions, extracted, and analyzed by
SDS-PAGE followed by autoradiography.
Yang et al.
2132 GENES & DEVELOPMENT
cessfully injected oocytes were identified by the pres-
ence of pink nuclei, reflecting the presence of hemoglo-
bin from the reticulocyte lysate. The nuclear and cyto-
plasmic fractions were analyzed by SDS-PAGE and
autoradiography for the presence of radiolabeled protein.
Only 12% of injected cyclin remained in the nuclei after
4 hr showing that Cyclin B1 can be actively exported
(Fig. 1B).
In the several cases examined thus far, nuclear protein
export requires the GTPase Ran/TC4. A Ran T24N mu-
tant, locked in its GDP-bound form, blocks export of
nuclear proteins, as does nuclear injection of RanGAP
protein, which accelerates hydrolysis of GTP by Ran
(Gorlich et al. 1997; Richards et al. 1997). To determine
whether cyclin nuclear export was affected by Ran–GDP,
we coinjected oocyte nuclei with 35S-labeled Cyclin B1
and purified T24N Ran protein or recombinant RanGap
protein. Both of these treatments led to a significant
diminution in the export of Cyclin B1 from the nucleus
into the cytoplasm (Fig. 2; data not shown). This suggests
that the GTP-bound form of Ran is likely to be required
for nuclear export of Cyclin B1, as has been shown for
other actively exported proteins (Gorlich et al. 1997; Ri-
chards et al. 1997).
Given the ability of Cyclin B1 to be exported from
nuclei, we suspected that the CRS might actually medi-
ate nuclear export of the cyclin, rather than blocking its
nuclear import. To determine whether the CRS could
promote nuclear export of a heterologous protein, we
linked the isolated CRS from Xenopus Cyclin B1 (amino
acids 76–125) to the carboxyl terminus of glutathione
S-transferase (GST). GST–CRS or GST protein alone was
then injected into nuclei (with dextran blue to identify
oocytes with injected nuclei), and nuclear and cytosolic
fractions were dissected at various times after injection
and examined for the distribution of injected protein by
immunoblotting with anti-GST sera. Although GST pro-
tein is small (25 kD), it is known to dimerize, and >90%
of the injected GST protein was retained in the nucleus
over a 7 hr time course (data not shown). Thus, GST
protein is effectively too large to exit the nucleus by
passive diffusion through pores, as has been noted by
others (Wen et al. 1995; Meyer et al. 1996). In contrast,
the injected GST–CRS protein was exported rapidly from
the nuclei (Fig 3). These data demonstrate that the CRS
can act as an autonomous NES.
Because the CRS could mediate nuclear export of Cy-
clin B1, we wished to determine whether the recently
identified NES from protein kinase inhibitor (PKI) (Wen
et al. 1995) could compete with Cyclin B1 for the nuclear
export machinery. Human serum albumin was conju-
gated to multiple copies of the NES from PKI, or to an
inactive scrambled mutant variant of the PKI NES
(called PKI NOS) to serve as a control. These conjugates
were then coinjected along with 35S-labeled Cyclin B1
into oocyte nuclei, and the location of the cyclin was
examined 3 hr and 5 hr after injection as described above.
Nuclear export of Cyclin B1 was delayed by the PKI–
NES, but not by the NOS mutant (Fig. 4A,B). Addition-
ally, microinjection of the PKI–NES conjugate into nu-
clei led to gradual nuclear accumulation of endogenous
Cyclin B1, whereas injection of the PKI–NOS conjugate
did not have this effect (Fig. 4C,D). This shows that Cy-
clin B1 can be imported into nuclei during interphase
and suggests that its predominantly cytoplasmic loca-
tion is promoted by nuclear export. Moreover, although
the PKI peptide did not completely eliminate Cyclin B1
export, its ability to compete with Cyclin B1 for nuclear
export suggests that Cyclin B1 and PKI utilize at least
some of the same nuclear export machinery.
Recently, it has been reported that nuclear export of
several substrates, including PKI, is mediated in part
through NES binding of the importin b family member,
CRM1 (Fornerod et al. 1997; Neville et al. 1997; Ossareh-
Nazari et al. 1997; Stade et al. 1997). Because the CRS
could mediate nuclear protein export, we suspected that
Figure 2. A GDP-bound form of Ran inhibits Cyclin B1 nuclear
export. (A) A mixture of 35S-labeled Cyclin B1 and 14C-labeled
BSA was coinjected into nuclei with recombinant T24N mutant
Ran protein (GDP-bound form). Oocytes were dissected 4 hr and
8 hr later and proteins were extracted and analyzed by SDS-
PAGE and autoradiography. (B) The bar graph represents a quan-
titation of the data in A, showing the percentage of Cyclin B1
remaining in nuclei after 0 and 8 hr.
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the CRS also might promote binding to CRM1. To de-
termine if this was the case, we coupled the GST–CRS
fusion protein to a glutathione–Sepharose resin and used
it as a bait to retrieve CRS-binding proteins from extracts
of Xenopus oocytes. After incubation in Xenopus oocyte
extracts, the beads were pelleted gently by centrifuga-
tion, washed extensively, and the bead-bound material
was processed for immunoblotting with anti-CRM1 an-
tisera. As shown in Figure 5A, the GST–CRS protein was
able to bind to CRM1. No specific interaction between
the CRS and other CRM1-related proteins implicated in
protein export, including RanBP7 (Gorlich et al. 1997)
and CAS (Scherf et al. 1996; Kutay et al. 1997) was de-
tected in parallel experiments. (Fig. 5B). In addition, no
bound CRM1 was detected with GST protein alone (Fig.
5A). Similarly, we found that recombinant GST–CRM1
protein linked to Sepharose beads could bind specifically
to full-length, in vitro-translated Cyclin B1 (Fig. 5E).
Thus, the nuclear export of Cyclin B1 may be mediated
by CRM1.
Recently, it has been reported that the drug leptomy-
cin B can specifically bind CRM1, thereby inhibiting
CRM1-dependent nuclear protein export. Consistent
with a role for CRM1 in export of Cyclin B1, we found
that export of radiolabeled Cyclin B1 was effectively in-
hibited by treatment of oocytes with 200 nM leptomycin
B (Fig. 5C,D). Moreover, leptomycin B treatment of egg
extracts also prevented binding of CRM1 to the B1 CRS
(Fig 5A).
Mutational analysis of a CRM1-dependent export sub-
strate, HTLV I Rex protein, has identified a loose con-
sensus NES (see Fig. 6A; Bogerd et al. 1996). By scanning
the Cyclin B1 sequence, we noted a sequence conform-
ing to the NES consensus within the CRS (amino acids
Figure 3. The CRS mediates nuclear export of Cyclin B1. (A)
The isolated CRS from Xenopus Cyclin B1 (amino acids 76–125)
was linked to the carboxyl terminus of GST. Either GST or
GST–CRS protein was injected into oocyte nuclei along with
14C-labeled BSA. Oocytes were dissected at 0, 30, and 50 min
after injection. Proteins were analyzed by SDS-PAGE followed
by immunoblotting with GST antibody and detection with 125I-
labeled protein A (quantitated by PhosphorImager). 14C-Labeled
BSA was detected by autoradiography. (B) The graph represents
a quantitation of the data in A, showing the percentage of in-
jected proteins remaining in nuclei at 0 and 50 min.
Figure 4. The PKI NES reduces nuclear ex-
port and induces nuclear accumulation of Cy-
clin B1. (A) Human serum albumin was con-
jugated with the NES peptide from PKI (HSA–
NES), or to an inactive scrambled mutant
variant of the PKI NES as the unexportable
control (HSA–NOS). The 35S-labeled Cyclin B1
and 14C-labeled BSA mixture was injected into
oocyte nuclei either with 8 µg/µl HSA–NES or
HSA–NOS. Oocytes were dissected at 0, 3, and
5 hr after injection, and proteins were analyzed
by SDS-PAGE followed by autoradiography.
(B) The data in A are graphed to show the
change in ratio of nuclear/cytoplasmic in-
jected Cyclin B1 over a 5-hr time course. (C)
HSA–NES or HSA–NOS (16 µg/µl) was in-
jected into oocyte nuclei with 10 µg/µl dex-
tran blue 2000 as an injection marker. Oocytes
were dissected at 0, 7, and 12 hr after injection
and proteins were analyzed by SDS-PAGE fol-
lowed by immunoblotting with Cyclin B1 an-
tibody. (D) The amount of cyclin present in the
nucleus at time 0 was quantitated; the in-
crease in nuclear cyclin after PKI NES injec-
tion is plotted as a percentage of cyclin quan-
tities initially found in the nucleus.
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108–117) of Xenopus Cyclin B1 (Fig. 6A). We mutated
one of the critical hydrophobic residues (F112) to an ala-
nine to determine whether this would affect the NES
function of the CRS. As shown in Figures 6, C and D,
35S-labeled F112A mutant Cyclin B1 injected into oocyte
nuclei was not exported. In addition, an F112A mutant
CRS variant no longer bound to CRM1 (Fig. 6E). Al-
though this mutation disrupted the ability of Cyclin B1
to export from nuclei, it did not perturb its ability to
interact with its binding partner, Cdc2 (Fig. 6B).
If cytoplasmic retention of Cyclin B1 is a consequence
of CRM1-mediated export, then leptomycin B might be
expected to induce nuclear accumulation of endogenous
Cyclin B1. Treatment of oocytes with 200 nM leptomy-
cin B induced gradual accumlation of nuclear Cyclin B1,
consistent with the hypothesis that Cyclin B1 can
shuttle through nuclei (Fig. 7A,B). We did not observe a
concomitant decrease in the cytoplasmic level of Cyclin
B1 because the cytoplasmic pool of Cyclin B1 in Xenopus
oocytes is quite large and the cytoplasmic/nuclear ratio
is >6:1. Injection of 35S-labeled Cyclin B1 into the cyto-
plasm of leptomycin B-treated oocytes or cytoplasmic
injection of the F112A mutant protein also led to a slow
nuclear accumulation of cyclin (data not shown). How-
ever, the nuclear accumulation of RanBP1, a shuttling
component of the nuclear trafficking machinery, was
considerably more striking, demonstrating that the
nuclear transport machinery of the oocyte was fully op-
erative (Fig. 7A,C). Therefore, we considered the possi-
bility that slow nuclear import of Cyclin B might be a
feature of the meiotically arrested G2 oocyte; progression
to meiotic GV breakdown (at the G2/M transition) can
take longer than 12 hr after treatment of oocytes with
the meiotic inducer progesterone. To keep Cyclin B1 in
the oocyte cytoplasm would require only that the rate of
export exceeds the rather slow import rate.
Given these data, we sought to examine the effects of
leptomycin B treatment on nuclear Cyclin B1 accumu-
lation in actively cycling somatic cells. Untreated HeLa
cells or HeLa cells treated with 20 nM leptomycin B for
varying times were lysed and separated into nuclear and
cytoplasmic fractions by centrifugation at 1000g for 10
min. The pelleting of nuclei was confirmed by staining
of the pellet with the fluorescent DNA intercalating dye
Hoechst 33258. Nuclei were washed twice in PBS, and
the nuclear and cytoplasmic fractions were resolved by
SDS-PAGE. Immunoblotting of these fractions with a
monoclonal antibody directed against human Cyclin B1
revealed that significant amounts of Cyclin B1 had ac-
cumulated in HeLa nuclei within 4 hr of leptomycin B
treatment (Fig. 8A,B; compare this with the 38 hr time
course in Xenopus oocytes). In addition, in HeLa cells,
cytoplasmic depletion of Cyclin B1 was seen concomi-
tant with nuclear accumulation. These results were con-
firmed by processing leptomycin B-treated HeLa cells for
indirect immunofluorescence with the anti-Cyclin B1
Figure 5. The nuclear export receptor, CRM1, mediates Cyclin B1
nuclear export through binding to CRS. (A) GST or GST–CRS fusion
protein was coupled to glutathione–Sepharose beads. Twenty micro-
liters of these resins were incubated in 100 µl of oocyte extract for 1
hr alone or in the presence of 200 nM leptomycin B. The beads were
then pelleted and washed three times with oocyte extract (EB) buffer.
The bead-bound proteins were analyzed by SDS-PAGE followed by
Western blotting with anti-human Crm1 antibody. (B) The same
samples as in A (with the exception of the leptomycin B-containing
sample) were immunoblotted with antisera directed against Ranbp7
and Cas. (C) Oocytes were incubated with 200 nM leptomycin B in
MB buffer for 2 hr before injection. A 35S-labeled Cyclin B1 and
14C-labeled BSA mixture was then injected into oocyte nuclei. Oocytes were dissected at 0, 3, and 7 hr after injection and proteins were
analyzed by SDS-PAGE followed by autoradiography. (D) The graph represents a quantitation of the data in C, showing the percentage
of injected proteins remaining in nuclei at 0 and 7 hr. (E) Human Crm1 was fused to the carboxyl terminus of GST protein. Either GST
alone or GST–Crm1 fusion protein was coupled to glutathione–Sepharose beads. Twenty microliters of each resin was incubated with
2 µl of 35S-labeled Cyclin B1 in 100 µl of buffer with 0.3 µg/µl Ran G19V (a mutant form of Ran that lacks GTPase activity and hence
remains constiutively GTP-bound) and 5 µM GTP at room temperature for 1 hr. The beads were then pelleted and washed three times
with oocyte extract buffer. The beads-bound proteins were analyzed by SDS-PAGE followed by autoradiography.
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monoclonal antibody. In untreated HeLa cells, Cyclin B1
is excluded from nuclei during interphase (Fig. 8C, top
panel), as reported previously. The sharp boundary
caused by the concentration of cyclin in perinuclear re-
gions creates the appearance of a nuclear rim; however,
this does not represent binding of Cyclin B1 to the
nuclear envelope. In untreated cells, the occasional pro-
phase cell could be seen staining with this antisera, con-
sistent with the reported rapid entry of Cyclin B1 into
nuclei just prior to entry into mitosis (data not shown;
Pines and Hunter 1991). However, when HeLa cells were
treated for 4 hr with leptomycin B, there was a dramatic
nuclear accumulation of Cyclin B1 in a large proportion
of interphase cells; a representative photomicrograph of
such cells is shown in Figure 8C (bottom panel). To fa-
cilitate comparison, treated and untreated cells were
photographed under the same conditions; this results in
a somewhat overexposed nuclear signal in the leptomy-
cin-treated cells in which cyclin is strongly concentrated
in the nucleus. These results are entirely consistent with
the idea that Cyclin B1 can cycle through the nucleus
during interphase. In support of this hypothesis, Pines
and colleagues, using time-lapse video microscopy, have
observed cycling of GFP-labeled Cyclin B1 through nu-
clei during interphase; this cycling is abolished by lep-
tomycin B treatment (J. Pines, pers. comm.).
As mentioned above, phosphorylation of four sites
(serines 94, 96, 101, and 113) within the CRS is thought
to affect Cyclin B1 localization (Li et al. 1997). Given our
findings, it seemed possible that phosphorylation might
modulate the ability of the CRS to bind to CRM1 and
thereby regulate its nuclear export rate. To test this
model, we produced isolated GST–CRS fusion proteins
in which the four serines in the CRS had been mutated
to either Ala (nonphosphorylatable) or Glu (which often
mimics constitutive phosphorylation). Beads coupled to
each of these fusion proteins were incubated in oocyte
extract and then examined for binding to CRM1, as de-
scribed above. We found that compared with the wild-
type CRS, the Ala mutant CRS bound more CRM1 from
the extract, whereas the Glu mutant bound much less
(Fig. 9A). Cyclin B1 containing the four Ala or four Glu
Figure 6. Cyclin B1 contains a Rev/Rex consensus NES within the CRS region. (A) The NESs of vertebrate Cyclin B1s were aligned
and compared with the consensus sequence for a functional Rev/Rex NES. (B) A full-length Cyclin B1 mutant in which the Phe residue
at position 112 was changed to Ala was translated in vitro and added to interphase extracts of Xenopus eggs (these contain Cdc2, but
lack mitotic cyclins). The 35S-labeled F112A mutant cyclin and wild-type cyclin were similarly retrieved from extracts by p13
Sepharose (which can only bind Cyclin B1 indirectly through interactions with its binding partner, Cdc2), but not by control Sepharose.
(C) A full-length Cyclin B1 mutant in which the conserved Phe-112 within CRS was mutated to Ala was translated in reticulocyte
lysates in the presence of [35S]methionine and mixed with 14C-labeled BSA, a nonexportable injection control. The mixture was
injected into Xenopus oocyte nuclei. After injection (0, 3, and 7 hr), the oocytes were dissected into cytoplasmic and nuclear fractions,
proteins were extracted, and samples were then analyzed by SDS-PAGE, followed by PhosphorImager quantitation. (D) The graph
represents a quantitation of the data in C, showing the percentage of injected proteins remaining in nuclei at the 0 and 7 hr time points.
(E) Phe-112 of Cyclin B1 was mutated to Ala and the isolated CRS containing this mutation was fused to the carboxyl terminus of GST
protein. GST alone, the wild-type GST–CRS protein, or F112A mutant GST–CRS protein were coupled to glutathione–Sepharose
beads. Twenty microliters of each resin was incubated in oocyte extract for 60 min and the beads were then pelleted and washed three
times with oocyte extract buffer. The bead-bound material was analyzed by SDS-PAGE followed by immunoblotting with anti-CRM1
antibody.
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mutations was then translated in vitro and injected into
oocyte nuclei to monitor the effect of the mutations on
cyclin export. The Ala mutant was exported very effi-
ciently, with only 11% remaining in the nucleus after 4
Figure 8. Leptomycin B treatment induces
nuclear accumulation of Cyclin B1 in HeLa cells.
(A) HeLa cells were treated with 20 nM leptomycin
B. At the indicated times, cells were collected and
separated into cytoplasmic and nuclear fractions.
Sampled were analyzed by SDS-PAGE followed by
Western blot with anti-human Cyclin B1 antibody
(Santa Cruz). All of the nuclear or cytoplasmic
fraction from 1.5 × 105 HeLa cells were loaded in
each lane, as indicated. (B) The graph represents a
quantitation of the data in A, showing the fold
increase of endogenous Cyclin B1 in HeLa cell nu-
clei following leptomycin B treatment. Note the
much shorter time course shown here than in the
Xenopus experiment in 7B (4 hr vs. 40 hr). (C) Ei-
ther untreated HeLa cells or HeLa cells treated for
4 hr with 20 nM leptomycin B were processed for
indirect immunofluorescence with a monoclonal
directed against human Cyclin B1, as described in
Materials and Methods. (Left) Cyclin B1 immuno-
fluorescence signals in representative interphase
cells either treated or untreated with leptomycin
B. (Right) The same cells stained with the DNA
intercalating dye, Hoechst 33258. Fluorescence
was observed and photographed with a 60× Pla-
napochromat objective and CCD camera.
Figure 7. Leptomycin B treatment induces en-
dogenous Cyclin B1 nuclear accumulation in
Xenopus oocytes. (A) Oocytes were treated with
200 nM leptomycin B in MB buffer. At the indi-
cated times after treatment, they were dissected
into cytoplasmic and nuclear fractions. Proteins
were extracted and analyzed by SDS-PAGE fol-
lowed by immunoblotting with anti-Xenopus
Cyclin B1 antibody. Although this antisera
cross-reacts with other proteins from the ex-
tract, the indicated band is Cyclin B1; this has
been confirmed by specific reactivity of the an-
tisera against recombinant Cyclin B1 and not
B2, and by observation of the periodic accumu-
lation and destruction of this band in cycling
extracts of Xenopus eggs. The samples blotted
with anti-cyclin sera were also immunoblotted
with anti-Ranbp1 sera, as a positive control pro-
tein for nuclear accumulation following lepto-
mycin B treatment. (B) The graph represents a
quantitation of the data in A, showing the fold
increase of endogenous Cyclin B1 accumulated
in nuclei at the indicated times after leptomy-
cin B treatment. For every oocyte nuclear
equivalent loaded on the gels, only one-eighth the amount of cytoplasm was loaded to facilitate observation of potential changes in
cytoplasmic levels of protein. (C) The graph represents a quantitation of the data in A, showing the fold increase of endogenous RanBP1
in nuclei following leptomycin B treatment.
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hr (Fig. 9B,C). The Glu mutant was exported poorly, with
86% remaining in the nucleus after 4 hr, as compared
with 51% of the wild-type protein (Fig. 9B,C). These data
are consistent with the hypothesis that phosphoryation
within the CRS impairs CRM1 binding and nuclear ex-
port.
One complication in the interpretation of these results
is that the localization of injected Cyclin B1 might, in
principle, be the combined result of nuclear export and
nuclear import rates, because Cyclin B1 can enter nuclei
during interphase (e.g., Figs. 7 and 8). Although data from
leptomycin B-treated oocytes suggests that the nuclear
import rate of wild-type Cyclin B1 is quite slow during
interphase, it remained formally possible that the Ala
and Glu mutants grossly altered the efficiency of nuclear
import of the exported Cyclin B1, rather than simply
affecting export. To circumvent this problem, we ana-
lyzed the trafficking of the GST–CRS fusion proteins,
because GST, which lacks a nuclear localization se-
quence, is not reimported into nuclei (Fig. 10A). Injec-
tion of the wild-type and mutant Glu GST–CRS fusion
proteins into oocyte nuclei revealed that the GST–CRS
Glu mutant was exported more slowly than the wild-
type GST–CRS (Fig. 10B).
In this experiment, the GST–CRS Ala mutant was ex-
ported from nuclei at a rate comparable with the wild-
type GST–CRS (Fig. 10B,C), with 7% of the wild-type
and 3% of the Ala mutant protein remaining in the
nucleus after 70 min (as compared with 25% of the Glu
mutant). This was somewhat surprising, because we had
observed that CRM1 from oocyte extracts bound prefer-
entially to the GST–CRS Ala mutant compared with the
wild-type GST–CRS (Fig. 9A). One possible explanation
for this discrepancy between CRM1-binding and nuclear
export rates would be that the degree of phosphorylation
of the wild-type GST–CRS was different in the CRM1-
binding experiment and in this export experiment. In the
CRM1-binding assay the GST–CRS was incubated in to-
tal oocyte extract, whereas in the export assay, the GST–
CRS was injected directly into nuclei. As expected, in
total oocyte extracts we found a robust kinase activity
able to phosphorylate the wild-type CRS (Fig. 10F). How-
ever, when the GST–CRS fusion protein was incubated
in equal amounts of total protein from separate nuclear
and cytoplasmic extracts (equivalent to nuclei from 45
oocytes and cytoplasm from 3.6 oocytes), seven times
more phosphate was incorporated into the CRS in the
cytoplasmic extract than in the presence of GV extract
(Fig. 10F). The low level of CRS phosphorylation ob-
served in nuclear extracts suggested that the large bolus
of GST–CRS protein that we injected into nuclei (Fig.
10B) may have overwhelmed the basal nuclear kinase
activity, thereby minimizing differences between the
(largely unphosphorylated) wild-type CRS protein and
(unphosphorylatable) Ala proteins. To test this hypoth-
esis we varied the amount of GST–CRS Ala and GST–
CRS wild-type proteins injected; reducing the level of
injected protein accentuated the difference in export
rates of the Ala and wild-type GST–CRS proteins. One
such experiment is shown in Figure 10D, in which 2.5-
fold less protein was injected than in the experiments
shown in Figure 10B. Under these circumstances, the
GST-CRS wild-type protein was exported more slowly
than the GST–CRS Ala mutant (Fig. 10D,E). Collec-
tively, these data lead us to postulate that CRS phos-
phorylation occurs at high levels in the cytoplasm and at
low levels in the nucleus during interphase.
Discussion
The CRS contains an NES
We have demonstrated that the CRS sequence of Cyclin
B1 can serve as a nuclear export sequence that targets
Figure 9. Phosphorylation within the CRS of Cyclin B1 im-
pairs its ability to bind to Crm1 and inhibits Cyclin B1 nuclear
export. (A) Mutant variants of the isolated CRS in which Ser-94,
Ser-96, Ser-101, and Ser-113 had all been changed to either Ala
or Glu were fused to the carboxyl terminus of GST protein.
Equal amounts of these fusion proteins or the wild-type GST–
CRS protein were coupled to glutathione–Sepharose beads.
Twenty microliters of each resin was incubated in oocyte ex-
tract for 60 min and the beads were then pelleted and washed
three times with oocyte extract buffer. The bead-bound material
was analyzed by SDS-PAGE followed by immunoblotting with
anti-CRM1 antibody. (B) Wild-type full-length Cyclin B1 or full-
length mutant variants in which all four sites of Ser phosphory-
lation within the CRS had been mutated to either Ala or Glu
was translated in the reticulocyte lysate in the presence of
[35S]methionine and mixed with 14C-labeled BSA, a nonexport-
able injection control. The mixture was injected into Xenopus
oocyte nuclei. At 0 and 4 hr after injection, the oocytes were
dissected into cytoplasmic and nuclear fractions; proteins were
extracted and samples were then analyzed by SDS-PAGE and
quantitated with a PhosphorImager. (C) The bar graph repre-
sents a quantitation of the data in B, showing the percentage of
each Cyclin B1 variant remaining in nuclei at 0 and 4 hr. Values
were normalized to coinjected 14C-labeled BSA.
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Cyclin B1 for CRM1-mediated nuclear export during in-
terphase. This suggests that the predominantly cytoplas-
mic localization of Cyclin B1 at this time is the result of
a dynamic traffic in which cyclin transits continually in
and out of the nucleus.
Recent studies have shown that the leucine-rich NES
of PKI directs nuclear export through association with
the export mediator CRM1 (Fornerod et al. 1997; Neville
et al. 1997; Ossareh-Nazari et al. 1997; Stade et al. 1997).
We have shown that the Cyclin B1 CRS also binds to
CRM1, and that cyclin export is delayed by an excess of
the PKI NES. We also found that cyclin export was
slowed by depletion of Ran–GTP, which was proposed to
be a cofactor for nuclear protein export (Richards et al.
1997). Although the sequence requirements for NES
function are only loosely defined, the CRS does contain
a sequence LCQAFSDVLI (residues 108–117 of Xenopus
Cyclin B1) that resembles the sequences critical for func-
tioning of the HIV Rev, HTLV I Rex, and PKI NESs, at
least in the spacing of hydrophobic amino acids (Fischer
et al. 1995; Wen et al. 1995; Bogerd et al. 1996). We found
that altering a critical hydrophobic residue in that se-
quence (F112) abolished both CRM1 binding and nuclear
export of Cyclin B1. Collectively, our data strongly sug-
gest that the Cyclin B1 CRS directs export from the
nucleus via a CRM1-mediated pathway similar to that
recently characterized for PKI.
Regulation of Cyclin B1 export through CRS
phosphorylation
Previous studies established that Cyclin B1 undergoes
phosphorylation at four serine residues within the CRS
(Izumi and Maller 1991; Li et al. 1995). Data from several
studies suggests that phosphorylation is a general feature
of B-type cyclins from many species (Meijer et al. 1989;
Gautier and Maller 1991; Izumi and Maller 1991), al-
though a function for these phosphorylations has not
been established. The data presented here indicate that
CRS phosphorylation can have a significant impact on
Cyclin B1 localization by reducing the affinity of Cyclin
B1 for CRM1, thereby decreasing its nuclear export rate.
A nonphosphorylatable mutant of Cyclin B1 maintained
high export rates, and prevented nuclear accumulation of
Cyclin B1, potentially explaining the failure of this mu-
tant to promote oocyte maturation. In contrast, a mutant
Figure 10. Phosphorylation of Cyclin B1
within the CRS directly modulates nuclear ex-
port. (A) GST protein was injected into the cy-
toplasm of oocytes and incubated for 30, 50, or
70 min. Oocytes were dissected into nuclear and
cytoplasmic fractions, resolved by SDS-PAGE
and immunoblotted with anti-GST sera. In-
jected GST remains cytoplasmic. (B) Fifty nano-
grams of GST protein fused to the wild-type,
Ala, or Glu mutant CRS sequences was injected
into oocyte nuclei along with 14C-labeled BSA.
Oocytes were dissected at 0, 30, 50, and 70 min
after injection and proteins were analyzed by
SDS-PAGE followed by immunoblotting with
GST antibody and 125I-labeled protein A or au-
toradiography to detect the 14C-labeled BSA. (C)
Quantitation of the data in B. The 125I-labeled
protein A signal was quantitated using a Phos-
phorImager. The bar graph shows the percent of
each injected cyclin variant remaining in the
nucleus immediately after and 70 min after in-
jection. (D) GST fused to the wild-type or Ala
mutant CRS sequences was injected into oocyte
nuclei along with 14C-labeled BSA. Oocytes
were dissected at 0, 20, 40, and 60 min after in-
jection and proteins were analyzed by SDS-
PAGE followed by Western blotting with GST
antibody or autoradiography to detect the 14C-
labeled BSA. Approximately 2.5-fold less protein
was injected in this experiment than the experi-
ment shown in B. (E) Quantitation of the data in
D. The bar graph shows the percent of each in-
jected cyclin variant remaining in the nucleus
immediately after and 60 min after injection. (F)
Oocytes were dissected into cytoplasmic and
nuclear fractions and extracts were prepared from each fraction or from whole oocytes. Each extract was diluted to 1.45 µg/µl. Twenty
microliters of GST–CRS wild-type beads was incubated in 45 µl of total (T), cytoplasmic (C), or nuclear (N) oocyte extract, 1 µM cold
ATP and 15 µCi of [g3P]ATP. After 20 min incubation at room temperature, beads were pelleted and washed with extract buffer three
times. The bead-bound material was analyzed by SDS-PAGE, developed by PhosphorImager and quantitated.
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designed to mimic full phosphorylation of Cyclin B1 in-
teracted much more weakly with CRM1 and was ex-
ported from the nucleus more slowly.
Whereas the cell cycle regulation of phosphorylation
at sites within the CRS has not been examined specifi-
cally, Kobayashi et al. (1991) noted a Cyclin B1 modifi-
cation (detected as a mobility shift of the protein in de-
naturing gels) in Xenopus oocytes that increased con-
comitant with germinal vesicle breakdown, perhaps
indicating an increase in CRS phosphorylation. Given
our findings, it is tempting to speculate that the rapid
accumulation of Cyclin B1 in the nucleus at the G2/M
transition could be governed by increasing phosphoryla-
tion of CRS residues, thereby reducing the affinity of
Cyclin B1 for CRM1 and decreasing nuclear export.
In addition to the CRS phosphorylation-mediated con-
trol of nuclear export rates, it is possible that nuclear
import rates are regulated and contribute to the relocal-
ization of Cyclin B1 at the G2/M transition. Neither
Cyclin B1 nor Cdc2 contains a classical NLS, and the
mechanism by which the Cdc2/Cyclin B1 complex en-
ters the nucleus is not yet clear. However, we have found
that the nuclear import factor, importin b, can bind to
Cdc2/Cyclin B1 complexes and experiments are in prog-
ress to determine whether this association reflects a role
for importins in mediating nuclear import of CDK/Cy-
clin complexes (J.D. Moore and S. Kornbluth, unpubl.).
Although the possibility that nuclear import can be regu-
lated by changes in CRS phosphorylation clearly merits
further investigation, it is interesting to note that Ala
and Glu mutant Cyclin B1 proteins bind equally well to
importin b (J.D. Moore and S. Kornbluth, unpubl.).
Localization of enzymes controlling Cyclin B1 CRS
phosphorylation
The identity of the kinase(s) responsible for phosphory-
lating sites within the CRS remains unknown. On the
basis of sequence comparisons with consensus substrate
sites, Li et al. (1997) suggested that a MAP kinase or
Cdc2/cyclin itself might phosphorylate Ser-94 or Ser-96
[as observed in vitro by Izumi and Maller (1991)], and
that casein kinase II might phosphorylate Ser-101 and
Ser-113 (Li et al. 1997). The latter site is adjacent to one
of the conserved hydrophobic residues in the part of the
CRS resembling the Rev and PKI NESs. It is unclear
which of the phosphorylation sites regulate the CRS–
CRM1 interaction, or whether multiple sites are in-
volved. Further studies into the particular sites involved
and the enzymes that control their phosphorylation are
underway.
Even without detailed information regarding the iden-
tity of the CRS kinase(s) and phosphatase(s), our data
suggest that a further layer of regulation may stem from
differential localization of these enzymes. At high levels
of injected protein, we found that the nuclear export
rates of wild-type and nonphosphorylatable GST–CRS
fusion proteins injected into the nucleus were very simi-
lar. Because phosphorylation of the wild-type CRS would
have slowed its export, this result suggested that the
CRS-directed kinase activities are relatively scarce in the
interphase nucleus or that CRS phosphatases are very
active in the nucleus, or both. Phosphorylation of the
CRS was very low in nuclear extracts compared with
that seen in cytoplasmic extracts, in which the CRS–
CRM1 interaction was impaired relative to the nonphos-
phorylatable mutant.
When we injected lower levels of GST–CRS protein,
the Ala and the wild-type proteins were exported at dif-
ferent rates, consistent with the results obtained with
the full-length cyclins. These data suggested that nuclear
kinases could phosphorylate the trace amounts of radio-
labeled full-length cyclins injected, but that the higher
amounts of injected GST–CRS protein exceeded the abil-
ity of the nuclear kinases to maintain a high stoichiom-
etries of phosphorylation on the wild-type GST–CRS.
It is not clear why the GST–CRS fusion proteins are
exported more rapidly than the full-length cyclin pro-
tein. The full-length cyclin has the capacity to be reim-
ported into nuclei after export, whereas the GST–CRS
fusion protein does not. However, the slow rate of
nuclear accumulation of Cyclin B1 in leptomycin B-
treated oocytes suggests that reimport may not have a
significant effect on total nuclear efflux during a typical
8 hr nuclear export experiment. Therefore, we consider it
possible that the context in which the CRS appears de-
termines the nuclear export rate of the CRS-containing
protein, or reimport of recently exported Cyclin B1 is
more rapid than import of the overall pool, reflected by
the slow accumulation of nonexportable cyclin. Al-
though the full-length cyclins and the GST–CRS pro-
teins were exported at different rates, the export rate of
wild-type CRS-containing proteins consistently ex-
ceeded that of Glu CRS-containing proteins. This sug-
gests that injected wild-type CRS-containing proteins
were never fully phosphorylated in any of our experi-
ments and that elevating phosphorylation of the CRS
within the nucleus could provide an effective means of
increasing nuclear accumulation of cyclin at the G2/M
transition.
Functional implications of Cyclin B1 export
The accumulation of nuclear Cyclin B1 after leptomycin
B treatment was less striking in Xenopus oocytes than in
HeLa cells. Whether this represents a species difference
or a difference in the import pathways operating in these
two cell types bears further investigation. However, in
both systems it appears that Cyclin B1 can be imported
into nuclei during interphase, despite the fact that the
steady state favors localization of Cyclin B1 to the cyto-
plasm.
It seems likely that the slow apparent import rate of
Cyclin B1 we observed in the leptomycin B-treated oo-
cytes reflects the nature of the G2-arrested oocyte sys-
tem: Unprimed Xenopus oocytes can take >12 hr to ac-
cumulate sufficient active nuclear Cdc2/Cyclin B for
germinal vesicle breakdown in response to progesterone
treatment, presumably reflecting, at least in part, the
slow accumulation of nuclear Cdc2/Cyclin B as oocytes
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transition from G2/M. The fact that the gradual accu-
mulation of Cyclin B1 in oocytes, which we observed
when nuclear export was blocked, may be physiologi-
cally significant is suggested by preliminary experiments
in which mRNA encoding the F112A mutant Cyclin B1
produced more rapid progression through the meiotic
G2/M transition than did similarly injected wild-type
Cyclin B1 mRNA (J. Yang and S. Kornbluth, unpubl.).
In the somatic cell cycle, nuclear shuttling during in-
terphase provides an appealing mechanism for coordinat-
ing nuclear and cytoplasmic aspects of entry into mito-
sis. The fact that a single Cdc2/cyclin complex can re-
ceive inputs from both nuclear and cytoplasmic
regulators provides a simple way of integrating different
signals from these compartments. For instance, entry
into mitosis is predicated on the completion of DNA
replication and repair of DNA damage (Murray et al.
1992). In the absence of these conditions, cell cycle
checkpoints act to inhibit Cdc2/cyclin activation. Tran-
sit of Cdc2/Cyclin B1 complexes through the nucleus
provides the opportunity for these complexes to continu-
ously sample the nuclear environment and receive
checkpoint information without invoking nucleocyto-
plasmic trafficking of checkpoint signals.
In addition to receiving inputs from different compart-
ments, the shuttling of Cdc2/Cyclin B1 complexes be-
tween nucleus and cytoplasm may help to ensure that
nuclear envelope breakdown, chromosome condensa-
tion, spindle formation, and other events of mitosis are
appropriately timed and that the nucleus and cytoplasm
enter mitosis simultaneously.
Materials and methods
In vitro translation
Xenopus Cyclin B1 wild-type, Ala, and Glu mutants were
kindly provided by Dr. D. Donoghue (University of California,
San Diego) in the vector SP64T, containing cyclin variants
cloned downstream of an SP6 promoter. 35S-Labeled proteins
were produced by use of the SP6-coupled TNT reticulocyte sys-
tem (Promega) according to manufacturer’s instructions.
Oocyte microinjection and subfractionation
Stage VI oocytes of Xenopus laevis were prepared for microin-
jection, as described (Swenson et al. 1989). Eight nanoliters of
protein sample was injected into oocyte nuclei along with 14C-
labeled BSA. Either 10 mg/ml dextran blue 2000 or red reticu-
locyte lysate was coinjected to mark the injected nuclei. Suc-
cessfully injected oocytes (those with blue or red nuclei) were
separated into nuclear and cytoplasmic fractions by manual dis-
section under mineral oil (Lund et al. 1990). Fractions from 5 to
10 oocytes were homogenized in buffer (65 mM Tris at pH 7.6,
10 mM EGTA at pH 8.0, 1 mM PMSF, 5 ng/µl aprotinin/leupep-
tin) and spun for 5 min at 13,000g to remove insoluble material.
The supernatants were precipitated with 3 volumes of acetone,
pelleted, and dried. The pellets were resuspended in 10 µl of
SDS-PAGE sample buffer per oocyte and analyzed by SDS-
PAGE, followed by autoradiography or Western blotting. In the
injection experiments, the absolute time course of Cyclin B
export varies between batches of oocytes (i.e., between frogs). In
all experiments in which we compare export rates in treated
oocytes (e.g., T24N, leptomycin B, NES) with those in untreated
oocytes, samples to be compared were done with the same batch
of oocytes. The same is true for experiments comparing the
nuclear export rates of different cyclin mutants. Multiple rep-
etitions of each experiment confirmed that the relative rates of
export of the mutants (or of wild-type cyclin in treated vs. un-
treated oocytes) were the same from experiment to experiment.
Site-directed mutagenesis
For construction of the Phe-112 → Ala mutant Cyclin B1, we
used ExSite PCR-Based Site-Directed Mutagenesis Kit (Strata-
gene). Wild-type Xenopus Cyclin B1 cDNA in the pSP64T vec-
tor was used as the template. The primers were (1) 58-GCTAGC-
GATGTCCTCATTCACGTTAAAGATGTTGATG, in which a
silent mutation was used to generate an NheI site to facilitate
mutant selection; and (2) 38-AGCCTGGCAGAGCTCAT-
CAGGGAGGCAACC.
Expression and purification of recombinant proteins
The isolated CRS from Xenopus Cyclin B1 (amino acids 76–
125), or mutant variants in which the four phosphorylated Ser
residues had been mutated to Glu or Ala were cloned into the
vector pGexKG to generate GST–CRS fusion proteins. All con-
structs and the vector alone were expressed in Topp 3. Esche-
richia coli (Stratagene). The recombinant fusion proteins were
expressed and purified as described (Solomon et al. 1992).
Preparation of total, cytoplasm, and nuclear oocyte extracts
Xenopus oocytes were prepared and manually dissected as de-
scribed above. Either total, cytoplasm or nuclear fractions were
homogenized in extract buffer (20 mM HEPES, 0.25 M sucrose,
0.1 M NaCl, 2.5 mM MgCl2 at pH 7.2) and centrifuged twice at
13,000g for 10 min. The clear supernatants were collected and
diluted to 1.45 mg/ml for assays of GST–CRS phosphorylation.
Phosphorylation assay
Twenty microliters of glutathione–Sepharose beads coupled to
GST or to GST–CRS wild-type, Ala, or Glu was incubated in 45
µl of extract with 1 µM ATP and 15 µCi [g32P]ATP at room
temperature for 20 min. The beads were then pelleted and
washed with 1 ml of extract buffer three times. The bead-bound
material was analyzed by SDS-PAGE followed by autoradiogra-
phy.
Pull-down experiments
GST fusion proteins were coupled to glutathione–Sepharose
beads and blocked with boiled fetal bovine serum to block non-
specific interactions of proteins with the sepharose beads. The
beads were then incubated with either oocyte extract or in vitro-
translated protein in boiled fetal bovine serum at 4°C for an
hour. The beads were then washed with EB buffer and the bind-
ing proteins were resolved by SDS-PAGE followed by immuno-
blotting or autoradiography.
Fractionation of HeLa cell extracts
Two subconfluent 10-cm dishes of HeLa cells were treated with
20 nM leptomycin B. At various timepoints, cells were washed
with PBS and scraped off the dish and harvested by centrifuga-
tion at 1 K for 10 min at 4°C. Cells were then resuspended in
hypotonic buffer (20 mM Tris-HCl at pH 7.4, 10 mM KCl, 1 mM
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EDTA, 10 µg/ml aprotinin, 10 µg/ml leupeptin) for 10 min on
ice and lysed by dounce homogenization. Nuclei were pelleted
by centrifugation at 1 K for 10 min and washed with PBS twice.
Both the cytoplasmic and nuclear fractions were mixed with
SDS sample buffer and analyzed by SDS-PAGE and immunob-
lotting. The nuclear and cytoplasmic fractions were normalized
to contain equal numbers of cell equivalents (∼1.5 × 105 cells/
lane).
Immunofluorescence
For immunolocalization of Cyclin B1, HeLa cells were grown to
subconfluency on coverslips in DMEM with 10% fetal bovine
serum. Where indicated, cells were incubated for 4 hr with the
same medium containing 20 ng/ml leptomycin B. Leptomycin-
treated or control coverslips were fixed at room temperature
with 4% paraformaldehyde and then permeabilized with cold
2% Triton X-100 in PBS. Nonspecific sites were blocked by
incubation with 2% BSA, 0.2% Triton X-100 in PBS, followed
by incubation with a monoclonal antibody to human Cyclin B1
(GNS1, 1/200; Santa Cruz Biotechnology). Bound antibody was
detected with RITC-conjugated antibody to mouse IgG1. Dur-
ing the final wash, cells were stained with Hoechst 33258 to
visualize the DNA, after which they were mounted on slides
with gelvatol.
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